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Abstract
Purpose—To evaluate the outcomes of phacoemulsification in patients with ocular graft-versus-
host disease (GVHD).
Methods—The occurrence of cataract, cataract surgery and its outcomes were analyzed in the 
medical records of 229 patients (458 eyes) with ocular GVHD. Outcome measures included pre- 
and postoperative corrected distance visual acuity (CDVA) and the rate of postoperative 
complications.
Results—From 458 eyes evaluated 58 were pseudophakic, from the 400 phakic eyes 238 (59%) 
presented with cataracts and 62 (26%) underwent cataract surgery. Analysis of postoperative 
complications and visual outcomes at one month was performed in 51 eyes in which detailed 
surgical and immediate postoperative records were available. Preoperatively, the mean CDVA was 
0.67±0.57 LogMAR (Snellen 20/93) and improved postoperatively to 0.17±0.18 (Snellen 20/29) at 
one month (P<0.0001), and to 0.13±0.14 (Snellen 20/26) by the final follow-up visit (P<0.0001). 
Postoperative complications included: corneal epithelial defects (8%), filamentary keratitis (6%), 
worsening of corneal epitheliopathy (16%), posterior capsular opacification (18%), and cystoid 
macular edema (4%). A corrected distance visual acuity of 20/30 or better was achieved in 87% of 
the eyes; suboptimal CDVA improvement was accounted by severe ocular surface disease, pre-
existing advanced glaucoma, and prior macular surgery.
Conclusions—Phacoemulsification in patients with chronic ocular GVHD is a safe and 
efficacious procedure resulting in significant visual improvement. Overall, postoperative adverse 
events responded well to timely management.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is an established treatment for various 
hematological disorders [1]. Advancements in transplantation techniques have led to an 
increase in the number of procedures performed annually and have contributed to the long-
term survival of these patients [1,2]. Therefore, long-term complications after HSCT are 
becoming the main factor affecting patients’ quality of life [3]. Chronic graft-versus-host 
disease (GVHD) has become a major cause of morbidity and mortality after allogeneic 
HSCT, this condition is originated by an immune response of donor T cells against the 
recipient’s tissues [4]. Ocular manifestations in patients with chronic GVHD are present in 
60–90% of cases [5]. Ocular GVHD commonly presents with eye discomfort, pain, 
grittiness, redness, light sensitivity, and blurred vision. Clinical signs include conjunctival 
hyperemia, corneal epitheliopathy, meibomian gland dysfunction, conjunctival and corneal 
scarring, and stromal ulceration, which negatively impact vision-related quality of life [4–6].
Posterior subcapsular (PSC) cataract is highly prevalent in patients undergoing HSCT, 
mostly due to irradiation and steroid treatment [7–9]. Furthermore, cataract has been 
reported as a major cause of decreased visual acuity in patients with systemic GVHD [10]. 
Consequently, a large number of patients are expected to undergo cataract surgery in the 
setting of ocular GVHD. Ocular surface manifestations of GVHD may affect the outcomes 
of cataract surgery and the postoperative course in these patients. Limited information 
regarding the outcomes of cataract surgery in patients with chronic ocular GVHD is 
available in the current literature [11–12]. The purpose of this study was to evaluate visual 
outcomes and post-operative complications of phacoemulsification in patients with chronic 
ocular GVHD.
Methods
We conducted a retrospective study that involved chart review of 229 patients with chronic 
ocular GVHD examined at the Cornea Service of the Massachusetts Eye and Ear Infirmary 
(MEEI) from May 2007 to December 2012. The study was approved by the Institutional 
Review Board and followed the tenets of the Declaration of Helsinki. Patients were selected 
according to the National Institutes of Health (NIH) diagnostic criteria for chronic ocular 
GVHD. These criteria are defined by a distinctive manifestation of systemic GVHD 
accompanied by: 1) new ocular sicca documented with a bilateral Schirmer test averaging 
≤5 mm, or 2) new onset of ocular sicca by slit-lamp examination with a bilateral Schirmer 
test averaging 6–10 mm [13].
We evaluated the presence and type of cataract in patients with ocular GVHD and the 
surgical outcomes in those who underwent cataract surgery. Data collected included 
demographic information, slit-lamp and fundus exam, change between preoperative and 
postoperative visual acuity, and intraoperative and postoperative findings. The surgical 
outcomes included corrected distance visual acuity at one month and last follow-up visits, 
and the intraoperative and postoperative complications. All postoperative ocular surface 
events occurring within 4 weeks postoperatively were considered related to the surgical 
procedure.
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Statistical Analysis
Mean corrected distance visual acuity values were calculated after converting recorded data 
from Snellen to LogMAR scale. Normality of the data was evaluated using the D’Agostino 
and Pearson omnibus test. The Wilcoxon signed-rank test was used to compare preoperative 
and postoperative corrected distance visual acuity and corneal fluorescein staining. A two-
sided P value of <0.05 was considered statistically significant. We calculated the occurrence 
of postoperative complications and expressed it as the proportion from the total eyes 
intervened.
Results
A total of 458 eyes with a diagnosis of chronic ocular graft-versus host disease were 
included, from which 58 eyes (13%) were pseudophakic at the initial visit. From the 400 
phakic eyes, 162 (40.5%) had a clear lens and 238 (59.5%) presented with one or more types 
of lens opacities as described in table 1. In total nuclear sclerosis was seen in 158 eyes 
(39.5%), posterior subcapsular cataract in 132 eyes (33%), and cortical cataract in 22 eyes 
(5.5%). Cataract surgery was performed in 62 eyes, representing 26% of all the eyes 
diagnosed with cataract. Posterior subcapsular cataract was present in all the operated eyes 
either alone (33 eyes) or in combination with nuclear sclerosis or cortical opacity (29 eyes). 
Analysis of postoperative complications and visual outcomes at one month was performed 
in 51 eyes with detailed surgical and immediate postoperative records. Six patients (11 eyes) 
who had the surgical procedure performed by their primary ophthalmologist but were 
followed at our ocular surface clinic were included in the visual acuity analyses for the 
preoperative and final visits.
At the time of cataract surgery the mean patient age was 50 ± 13 years (range: 22–72). The 
mean interval between HSCT and development of ocular GVHD in patients undergoing 
cataract surgery was 19 ± 28 months (median: 11, range: 1–159 months). All patients 
presented clinical features of chronic ocular GVHD, except one patient who first presented 
with acute ocular GVHD but later developed chronic ocular GVHD. Phacoemulsification 
was performed 42 ± 33 months (median: 32, range: 19–251) after HSCT and 23 ± 19 
months (median: 19, range: 2–91) after the diagnosis of ocular GVHD. The mean patient 
follow-up after cataract surgery was 12 ± 13 months (1–50). The primary disorder for which 
HSCT was performed, conditioning regimens, and extraocular GVHD involvement are 
shown in Table 2; other concurrent pathological conditions in the eyes undergoing cataract 
surgery are shown in Table 3.
Surgical procedure
In all eyes undergoing cataract surgery adequate control of ocular surface disease was 
achieved preoperatively. Preoperative topical and systemic therapy for ocular GVHD and 
concurrent systemic GVHD are shown in Table 4. Treatment with topical autologous serum 
was discontinued three days prior and until one week after surgery since it is rich in protein 
and growth factors, and hence may increase the risk of microbial colonization and infection 
in the setting of intraocular surgery [14,15]. Scleral contact lenses were removed 
immediately before intraocular lens calculation to ensure an even ocular surface and 
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accurate biometry, to subsequently resume their use until the day of surgery. 
Postoperatively, scleral contact lens wear was restarted after one week if the corneal wound 
was sutured or after three to four weeks otherwise. Phacoemulsification through a clear 
corneal incision with posterior chamber intraocular lens implantation was performed in all 
the eyes. Postoperatively, 1% topical prednisolone acetate was prescribed four times a day 
tapered over four weeks, and topical fluroquinolone four times a day for one week. Patients 
were examined postoperatively at day one, week one, and one month after the surgery unless 
otherwise required. After one month, the frequency of visits depended on the status of the 
ocular surface.
Visual outcomes
The mean preoperative CDVA was 0.67 ± 0.57 LogMAR (Snellen 20/93) and improved to 
0.17 ± 0.18 (Snellen 20/29) at one month postoperatively (P<0.0001), and to 0.13 ± 0.14 
(Snellen 20/26) at the final follow-up visit (P<0.0001). Table 5 shows the visual acuities at 
one-month and the final visits. By the final visit 54 eyes (87%) had achieved a visual acuity 
of 20/30 or better. From the eyes (8) that did not achieve a visual acuity of 20/30 or better, 
five eyes presented with concurrent pathologies such as advanced glaucoma (4) and prior 
macular surgery (1), while three eyes had severe dry eye with corneal epitheliopathy, some 
of which required management with scleral contact lens.
Intraoperative findings
There were no severe intraoperative complications. One eye required limited anterior 
vitrectomy with intraocular lens implantation in the sulcus due to a posterior capsular tear.
Postoperative findings
Corneal epithelial defects—Corneal epithelial defects ≥ 1 mm were noted in four eyes 
(8%) at postoperative days two (2 eyes), seven (1) and 14 (1). Epithelial defects were 
located centrally in all the eyes and resolved within a week after treatment with lubrication, 
antibiotic ointment, and bandage contact lens (3 eyes).
Filamentary keratitis—Filamentary keratitis was noted in three eyes (6%) at 
postoperative days one (1 eye) and 14 (2).
Corneal punctate keratitis—Worsening of corneal epitheliopathy was noted in eight 
eyes (16%) at postoperative weeks one (6 eyes) and four (2). We were not able to compare 
the pre and postoperative corneal fluorescein staining in all patients due to lack of consistent 
data recorded in the same scheme for all visits (e.g., NEI or Oxford scheme). Nonetheless, in 
45% of the cases the preoperative and postoperative (one week and one month) corneal 
fluorescein staining values were available in the modified Oxford scheme. In this subgroup 
of patients, the mean corneal fluorescein staining increased from 1.02 ± 0.77 Oxford units 
preoperatively to 1.65 ± 1.29 units at one week postoperatively (P=0.04), and subsequently 
decreased to 1.30 ± 1.05 units at one month postoperatively (P=0.23, compared to the 
preoperative score). From eight eyes with exacerbated punctate keratitis after surgery, two 
eyes had been treated preoperatively with autologous serum. After restarting the 
preoperative topical therapy, including autologous serum, both eyes reached preoperative 
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punctate keratitis levels by eight weeks. Exacerbation of punctate keratitis after surgery 
responded to treatment with one or more of the following: preservative-free lubricant eye 
drops, topical corticosteroids, punctal plugs, resumption of topical autologous serum, and 
scleral or bandage contact lenses.
Posterior capsular opacification (PCO)—Vision impairing posterior capsular 
opacification (PCO) where laser capsulotomy was indicated was present in nine eyes (18%) 
and was noted between one to eight months after surgery.
Cystoid macular edema (CME)—Cystoid macular edema was diagnosed when cystic 
changes were evident either by fundoscopy or by optical coherence tomography, and when 
the vision acuity was ≤ 20/40. CME was noted in the two eyes (4%) of the same patient at 
months five and seven postoperatively. Both eyes underwent uneventful 
phacoemulsification, and were treated with YAG laser capsulotomy three months after the 
surgery due to PCO. After unsatisfactory visual acuity improvement, a macular 
comprehensive evaluation revealed the presence of CME. However, fundus examination 
also revealed retinal microaneurysms and microhemorrhages in both eyes, while the 
fluorescein angiography revealed perifoveal telengiectatic vessels; a diagnosis of radiation 
retinopathy was made by the MEEI Retina Service. The CME responded to topical non-
steroidal anti-inflammatory treatment only in one eye but required subtenonian 
triamcinolone and intravitreal bevacizumab in the fellow eye. At the final follow-up visit 
both eyes showed improvement with visual acuity of 20/25 and 20/30, respectively.
Discussion
In this retrospective study cataract was present in 59% of the eyes of patients with chronic 
ocular GVHD. Twenty-six percent of these eyes underwent cataract surgery with good 
visual outcomes, represented by a postoperative corrected distance visual acuity of 20/30 or 
better in 87% of the eyes. From eight eyes (13%) that did not achieve visual acuity of 20/30, 
three eyes (5%) presented severe ocular surface disease, four eyes (6%) advanced glaucoma, 
and one eye (2%) previous macular surgery (Table 3).
We observed nuclear sclerosis in 39.5% of the eyes with ocular GVHD, which is in 
concordance with the prevalence of nuclear sclerosis reported in the general population (19 
to 51%), most likely reflecting the aging changes in the lens [16,17]. However, the 
prevalence of posterior subcapsular cataract noted in our cohort (33%) is 5 times higher than 
reported in the general population [16,17]. Our study is consistent with other studies 
reporting a high prevalence of up to 48% of PSC cataract in patients with systemic GVHD 
[8,10]. This can be explained, to a large degree, by the known association between exposure 
to radiation and systemic corticosteroids and the development of posterior subcapsular 
cataract in patients receiving hematopoietic stem cell transplants [8, 18–20]. In the present 
study, 47% of the eyes diagnosed with PSC cataract underwent cataract surgery at a mean 
age of 50 years, a considerably younger age when compared to the mean age of individuals 
undergoing cataract surgery in the general population [21,22].
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Cataract surgery can induce or aggravate preexisting dry eye disease [23]. Ocular surface 
complications such as punctate keratitis, recurrent epithelial defects, filamentary keratitis 
and corneal melting have been reported after cataract surgery in patients with dry eye 
disease, especially in those associated with systemic disorders such as Sjogrens syndrome 
and rheumatoid arthritis [24–26]. In patients with preexisting aqueous deficiency and an 
unstable tear film undergoing cataract surgery the inflicted insult due to incision (nerve 
damage), ocular surface exposure and toxicity from eye drops may pose the cornea in a 
vulnerable situation for epithelial breakdown [23,27]. In our series, the incidence of 
epithelial defects after cataract surgery was 8%. Other studies on cataract surgery in patients 
with dry eyes after bone marrow transplantation have reported epithelial defects in 0–3% of 
the eyes [11,12] and one study in patients with dry eye secondary to connective tissue 
disorders and older age reported epithelial defects in 32% of cases [26]. In the current study, 
three of the four eyes that developed epithelial defects were being treated with scleral 
contact lenses and two with topical autologous serum prior to the surgery, which is 
indicative of severe ocular surface disease. Additionally, cessation of treatment with scleral 
lenses and topical autologous serum in the early postoperative period might have contributed 
to the development of epithelial defects. However, all the epithelial defects responded 
satisfactorily to adequate treatment and resolved within one week. Based on the observations 
of the current and other studies, the evidence suggests that the severity of dry eye disease at 
the time of surgery can largely influence the occurrence of postoperative epithelial 
breakdown. Ocular inflammation triggers mucus production and adherence of the mucus 
strands to the compromised epithelium leads to filamentary keratitis, which was noted in 6% 
of the cases in the early postoperative period.
We noticed worsening of corneal epitheliopathy in 16% of the eyes in the early 
postoperative period. The comparison between the pre and postoperative corneal fluorescein 
staining scores revealed that the mean corneal fluorescein staining increased statistically 
significantly one week after the cataract surgery but subsequently decreased at one month 
postoperatively, showing at this later point no statistically significant difference with the 
preoperative scores. This pattern is similar to that described in the general population after 
phacoemulsification [28].
Vision impairing PCO that required YAG laser capsulotomy developed in 18% of the 
operated eyes and was noted between one and eight months after surgery. The general 
incidence of PCO reported within one year of cataract surgery varies from 2–11% 
[29,30,31]. A meta-analysis by Schaumberg et al. reported an estimate of PCO incidence of 
11.8% after one year of surgery and 20.7% after three years [32]. PCO development is 
influenced by several factors such as patient age, type of surgery, materials and designs of 
intraocular lenses, and the follow-up period making it difficult to compare the incidence 
among different studies. In the current study a higher incidence of PCO, when compared to 
the incidence reported for the general population, is likely related to the high prevalence of 
PSC cataract, treatment with systemic corticosteroids, and to a younger mean age, all of 
which have been linked to posterior capsular opacification [33,34,35]. Interestingly, the 18% 
PCO incidence noted in this study is much lower than the 44% PCO incidence reported by 
our group in 2001 in recipients of bone marrow transplants that underwent cataract surgery, 
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this reduction in the incidence of PCO may be influenced by advancement in surgical 
techniques and intraocular lenses as reported for the general population. [11,36]
The patient who presented with bilateral cystoid macular edema several months after 
cataract surgery was ultimately diagnosed with bilateral radiation retinopathy. This patient 
had history of standard treatment with fractionated total body irradiation as a part of pre-
transplant conditioning regimen but additionally received cranial radiation. Penn et al. 
reported a similar case with bilateral CME in one patient with ocular GVHD after cataract 
surgery, however the CME in that patient was noted within two months of cataract surgery 
and there is no mention of radiation retinopathy [12]. It is unlikely that the occurrence of 
bilateral CME in this case was related to the cataract surgery given the delayed appearance 
after six months and the concurrent diagnosis of associated radiation retinopathy. Radiation 
is a well-known factor that inflicts damage to the retinal vascular endothelium and leads to 
capillary occlusion, microaneurysm formation, and telengiectatic vessels, ultimately leading 
to leakage and macular edema [37]. However, it is possible that radiation-induced retinal 
compromise may predispose to macular edema development in the setting of otherwise 
uncomplicated cataract surgery. Awareness of this potential risk and assessment of the 
macular condition in previously irradiated patients undergoing cataract surgery (e.g., by 
optical coherence tomography) may be of help to better understand the patient’s ocular 
condition, and to implement the right procedures to improve the ultimate visual prognosis.
The present study has limitations inherent to its retrospective design, including the 
variability of postoperative follow-up within the cohort. It is important to emphasize that it 
is difficult for the ophthalmologist to follow-up patients with ocular GVHD, these patients 
are usually followed up in oncology or internal medicine departments, have multiple serious 
systemic conditions that frequently result in hospitalization or mortality, thus leading to 
variable follow-ups to an eye clinic. However, we believe that despite the limitations, the 
evidence from this large cohort provides valuable clinical data regarding the visual potential 
and expected complications of cataract surgery in patients with ocular surface disease 
secondary to GVHD. To overcome the most common limitations we face with these 
patients, we propose the creation of a multicentric registry that facilitates accessibility to 
accurate and continuously updated data from large cohorts, hence improving our 
understanding of ocular GVHD, its natural history, and the impact of cataract surgery and 
other interventions.
In summary, visual outcomes of phacoemulsification in patients with chronic ocular graft-
versus-host disease are excellent, resulting in visual acuities of 20/30 or better in 95% of 
eyes without any concurrent pathological condition other than GVHD. No serious adverse 
events occurred and ocular surface complications responded well to appropriate 
management. Awareness of concurrent co-morbidities, such as severe ocular surface 
impairment or posterior segment conditions, may help to identify cases with a more reserved 
visual prognosis. Herein, we show that optimal preoperative stabilization of the ocular 
surface and timely identification and management of complications proves 
phacoemulsification an efficacious procedure in patients with ocular graft-versus-host 
disease.
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Table 1
Summary of the lens opacities in patients with ocular GVHD
Lens condition Total number of eyes (%) (N= 400)
Clear lens 162 (40.5)
Nuclear sclerotic cataract 90 (22.5)
Posterior subcapsular cataract 78 (19.5)
Cortical cataract 2 (0.5)
Nuclear sclerotic + Posterior subcapsular cataract 48 (12)
Nuclear sclerotic +Cortical cataract 14 (3.5)
Nuclear sclerotic + Posterior subcapsular + Cortical cataract 6 (1.5)
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Table 2
Transplant details in patients undergoing cataract surgery
Parameter N=36 (%)
Primary disorder
 Acute Myeloid Leukemia 17 (47)
 Chronic Lymphoid Leukemia 6 (17)
 Acute Lymphoid Leukemia 4 (11)
 Non-Hodgkin’s Lymphoma 5 (14)
 Chronic Myeloid Leukemia 2 (5.5)
 Myelodysplastic syndrome 2 (5.5)
Conditioning regimen
 Total body irradiation + Chemotherapy 16 (44)
 Chemotherapy alone 20 (56)
Systemic graft-versus-host disease
 Skin 26 (72)
 Mouth 25 (69)
 Liver 13 (36)
 Gastrointestinal tract 7 (19)
 Lung 3 (8)
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Table 3
Concurrent pathological findings in the eyes undergoing cataract surgery
Preoperative findings No. of eyes (%)N=62
Meibomian gland dysfunction 62 (100)
Superficial punctate keratopathy 61 (98)
Conjunctival hyperemia 36 (58)
Lid margin scarring 10 (16)
Subconjunctival fibrosis 9 (14.5)
Conjunctivochalasis 9 (14.5)
Filamentary keratitis† 9 (14.5)
Glaucoma 4 (6)
Healed adherent leucoma 1 (2)
Corneal scar post healed corneal ulcer 1(2)
Previous corneal perforation requiring PKP 1 (2)
Resolved central serous chorioretinopathy 1 (2)
Post macular hole surgery 1 (2)
†
Filamentary keratitis was resolved prior to cataract surgery in all eyes. PKP: Penetrating keratoplasty
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Table 4
Patients’ preoperative topical and systemic therapy for ocular and systemic GVHD.
Local treatments for ocular GVHD No. of cases (%)
Topical lubricants 62 (100)
Punctal occlusion 42 (67.7)
Topical anakinra 27 (43.5)
Topical autologous serum 23 (37)
Antibiotic ointment 20 (32)
Topical cyclosporine 17 (27)
Topical corticosteroids 9 (14.5)
Scleral lens 9 (14.5)
Mucolytic (10% N-acetylcysteine) therapy 5 (8)
Systemic treatments for ocular and concurrent systemic GVHD
Corticosteroids 47 (76)
Mycophenolate mofetil 29 (47)
Doxycycline 21 (34)
Sirolimus 21 (34)
Tacrolimus 18 (29)
Graefes Arch Clin Exp Ophthalmol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Saboo et al. Page 14
Table 5
Preoperative and postoperative corrected distance visual acuity
Visual acuity Snellen Preoperative eyes (%)N=62 eyes
Postoperative
1 month
N=51 eyes (%)
Final visit
N=62 eyes (%)
<20/200 7 (11) 0 (0) 0 (0)
<20/80–20/200 18 (29) 0 (0) 0 (0)
<20/30–20/80 28 (45) 16 (31) 8 (13)
≥20/30 9 (15) 35 (69) 52 (87)
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